Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tremelimumab in Advanced Refractory/Relapsed Melanoma
NCT00254579Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2005
- Primary completion
- Dec 2009
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 9
01
Overview
A Phase 2 trial of tremelimumab in melanoma, sponsored by AstraZeneca. Started Dec 2005; status: completed.
02
Drugs
tremelimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00254579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00254579.